Search

Ether Lipids Hyperactivate Dendritic Cells - Corner Therapeutics

The USPTO published patent application US20260097111A1 by Corner Therapeutics, Inc. on April 9, 2026, covering ether lipid (ETL) and ether phospholipid (ETPL) compounds for hyperactivating mammalian dendritic cells, including compositions combined with pathogen recognition receptor agonists, antigens, and dendritic cells. The application was originally filed on October 18, 2023.

Silicon Nanoparticle Delivery System for Controlled Release of Nucleic Acids Including siRNA and mRNA

The USPTO published patent application US20260096997A1 assigned to SISAF LIMITED, filed November 6, 2025. The application covers a composition for controlled release of nucleic acids such as short interfering RNA (siRNA) or messenger RNA (mRNA), comprising silicon nanoparticles comprising at least 50% by weight silicon, at least one amino acid, and at least one lipid. The CPC classifications indicate primary focus on pharmaceutical preparations (A61K) and therapeutic uses including ophthalmological applications (A61P 27/02).

Parsnip Extract Composition for Intestinal Health and Leaky Gut Treatment

USPTO published patent application US20260097089A1 for a composition containing parsnip extract as an active ingredient. The composition is designed to reduce tight junction protein downregulation, promote beneficial intestinal bacteria proliferation, maintain acidic intestinal environment, and reduce intestinal permeability. The application indicates the composition may be used in foods, feeds, pharmaceuticals, or quasi-drugs for improving intestinal health and preventing or treating leaky gut syndrome, obesity, or metabolic diseases.

Herbal Medicine Extracts RM01 for Alzheimer's Treatment

The USPTO has published patent application US20260097090A1, filed September 26, 2023, and published April 9, 2026, covering herbal extract compositions for treating neurodegenerative diseases including Alzheimer's disease. The composition includes extracts from Ophiopogon japonicus, Barbary Wolfberry, Rhizoma Acori tatarinowii, and Codonopsis pilosula. This is a patent application publication, not a granted patent, and does not confer any regulatory approval for the claimed treatments.

Modified oHSV with HRG for Cancer Therapy

The USPTO published patent application US20260097088A1 for a modified oncolytic herpes simplex virus (oHSV) engineered with an expression cassette encoding histidine-rich glycoprotein (HRG) for use in cancer therapy. The invention, filed on August 17, 2023 (Application No. 19113359), leverages virotherapy to selectively target and lyse cancer cells while sparing normal cells. The inventors are Chun-Yu Chen, Pin-Yi Wang, and Timothy P. Cripe.

Cancer Treatment Using Thyroid Hormone Analogs T2 and RT3

USPTO published patent application US20260097100A1 filed by Keith Roger Latham and Regina L. Garland on September 25, 2025, covering methods and compositions for treating cancer through induction of tumor cell differentiation using thyroid hormone analogs such as T2 and RT3. The application discloses pharmaceutical compositions including topical formulations for skin cancer and delivery systems for systemic administration.

Reboxetine Patent Application for Narcolepsy and Cataplexy Treatment

USPTO published patent application US20260097040A1 by Herriot Tabuteau covering methods of treating narcolepsy with cataplexy using reboxetine or esreboxetine. The application includes pharmaceutical compositions and instructions for use in treating the condition. Filing date was December 11, 2025, with publication on April 9, 2026.

Compositions and Methods for Reprogramming Diseased Musculoskeletal Cells

USPTO published patent application US20260097131A1 titled 'Compositions and Methods for Reprogramming Diseased Musculoskeletal Cells.' The application (filed December 11, 2025) discloses compositions and methods for reprogramming diseased musculoskeletal cells both in vitro and in vivo using non-viral delivery of polynucleotides encoding transcription factors. The patent application is now publicly available.

Peptide Analogue for Treatment of Diabetes or Obesity

USPTO published patent application US20260097101A1 for a peptide analogue of pancreatic polypeptide (PP) intended for treating diabetes or obesity. Filed September 6, 2023 under application number 19110570, the invention also covers methods of treatment and use in manufacturing a medicament for these conditions.

Methods for Treating Fatty Liver Disease (NASH) with Resmetirom

USPTO published patent application US20260097039A1 disclosing methods of treating fatty liver disease (non-alcoholic steatohepatitis/NASH) and improving liver fibrosis using resmetirom (2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile) or its pharmaceutical salts. Inventors: Rebecca Taub and Dominic Labriola. Application filed December 10, 2025, and published April 9, 2026. This is a publication of a patent application, not a granted patent.